4 Aug 2023 , 11:31 AM
The initial public offer (IPO) of Concord Biotech has open for subscription on August 4 and will conclude on August 8. The company is raising Rs 1551 crore from this book building offer and has fixed IPO price band at Rs 705-741 per share. Click here to subscribe the IPO.
On day 1 by 11.30 AM, the issue has been subscribed 0.14 times. The retail portion of the IPO has been subscribed 0.21 times, NII received bids for 0.16 times while employee portion has been fully subscribed in the first hour of opening with 2.27 times subscription. QIP portion has received bids for 560 equity shares against 41,83,130 shares available for subscription.
As the company’s initial public offering (IPO) bidding commenced on August 4, investor enthusiasm has been fueled by the participation of renowned entities like Helix Investment Holdings (managed by Quadria Capital Fund LP, a healthcare-focused private equity fund) and Ontario Fund.
The company benefits from the support of RARE Trusts, the investment firm associated with the late Rakesh Jhunjhunwala, a prominent figure in the financial world.
Concord Biotech IPO important details:
Open date | 4 August 2023 |
Close date | 8 August 2023 |
Lot size | 20 shares |
IPO size (Rs crore) | Rs 1551 crore |
IPO price range (Rs) | Rs 705-741 |
Minimum investment | Rs 14,820 |
Basis of allotment date | 11 August 2023 |
Refunds date | 14 August 2023 |
Credit to demat account date | 17 August 2023 |
Listing date | 18 August 2023 |
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.